Viral infection induces type I interferons (IFN- and IFN-) that recruit unexposed cells in a self-amplifying response. We report that the transcription factor MafB thwarts auto-amplification by a metastable switch activity. MafB acted as a weak positive basal regulator of transcription at the IFNB1 promoter through activity at transcription factor AP-1-like sites. Interferon elicitors recruited the transcription factor IRF3 to the promoter, whereupon MafB acted as a transcriptional antagonist, impairing the interaction of coactivators with IRF3. Mathematical modeling supported the view that prepositioning of MafB on the promoter allows the system to respond rapidly to fluctuations in IRF3 activity. Higher expression of MafB in human pancreatic islet beta cells might increase cellular vulnerability to viral infections associated with the etiology of type 1 diabetes.
Viral infection in mammalian cells elicits responses by strainnonspecific cellular pattern-recognition receptors, including Toll-like receptors (TLRs), RIG-like helicases, double-strand-specific kinases and cytosolic DNA receptors 1 . Engagement of these sensors triggers an intracellular signaling cascade that leads to the production of type I interferon and proinflammatory cytokines. The cytokines further activate a subset of genes that enforce and propagate an antiviral state throughout the host, thereby activating the first line of defense against viral pathogens. Although rapid and sensitive cellular induction of cytokines after viral infection is essential for efficient suppression of viral propagation, mammalian cells have also developed many mechanisms to prevent autonomous induction and excess production of type I interferon 2 . Despite substantial advances over the past decade in understanding cellular regulation of the induction and signaling of type I interferon, the components of the pathways involved have not been fully elucidated.
In this study, a genome-wide screen of potential gene products interacting with the human type I interferon transcriptional response identified many candidates with negative action at the promoter of IFNB1, the gene encoding interferon-β (IFN-β). One of these, MafB, a member of the family of Maf transcription factors, is the subject of this report. Members of the Maf family of proto-oncogene products mediate both oncogenic transformation and terminal differentiation 3, 4 . MafB is ubiquitously expressed in human tissues 5 , but is found in especially large amounts in myeloid cells, and facilitates the establishment and maintenance of the monocyte-macrophage lineage 6 . MafB has also been linked to the formation of pancreatic islet beta cells 7, 8 . We report here that MafB is a regulator of type I interferon transcription with a dual mode of action as both activator and coactivation inhibitor.
RESULTS

MafB is a negative regulator of type I interferon
We identified candidate positive and negative regulators of the transcription of type I interferon genes by a transcriptional reporter screen in which we transfected 17,184 individual cDNAs encoding human proteins together with an IFNB1 luciferase reporter into 293ETN cells (which are derived from 293 human embryonic kidney cells). Luciferase activity measured at 2 d after transfection provided a sensitive and reliable measure of transcriptional enhancement or repression. The screen identified known activators and repressors of IFNB1 transcription as well as proteins to which no activity had previously been ascribed. Among the latter, MafB consistently and prominently inhibited the interferon transcriptional response, and we selected this protein for further study.
Overexpression of human MafB in 293ETN cells weakly enhanced basal activity of the IFNB1 promoter in a dose-dependent manner (Fig. 1a) . In contrast, when we primed the cells with the synthetic RNA duplex poly(I:C) at 24 h after transfection, coexpressed MafB strongly inhibited activation (Fig. 1a) . MafB-mediated inhibition did not reflect a general repression of transcription, as the activity of a luciferase reporter expressed under the control of a herpes simplex thymidine kinase promoter was not affected by MafB coexpression in either the presence or the absence of poly(I:C) ( Fig. 1b) . In addition, the activity of luciferase reporters under the control of synthetic promoters responsive to the tumor suppressor p53 or the transcription factor NF-κB was not suppressed by coexpressed MafB (Fig. 1b) . MafB strongly inhibited IFNB1 activation triggered by other IFNB1 inducers, including constitutively active amino-terminal (N-terminal) forms of the RNA helicases RIG-I and Mda5 (refs. 9,10; RIG-I(N) and Mda5(N), respectively), and Newcastle disease virus (NDV; Fig. 1c ). We obtained similar results with HEC1B human endometrial adenocarcinoma cells ( Supplementary Fig. 1a ), which lack a functional type I interferon receptor; this result indicated that suppression of extracellular feedback mediated by IFN-β secretion is not a required element of the inhibition process. Mouse MafB also inhibited poly(I:C)-and RIG-I(N)-mediated activation of Ifnb1 in mouse macrophage cell lines ( Supplementary  Fig. 1b ). The action of human MafB on the transcription of endogenous IFNB1 and IFNA1 recapitulated the results obtained with the luciferase reporter. In unstimulated 293ETN cells, basal expression of IFN-β and IFN-α1 mRNA was slightly increased by MafB overexpression, whereas poly(I:C)-mediated activation was severely impaired (Fig. 1d,e ). The luciferase activity of a recombinant vesicular stomatitis virus (VSV-Luc) was enhanced by coexpression of MafB, whereas expression of IRF3, a positive regulator of type I interferon induction, suppressed VSVdependent luciferase expression ( Fig. 1f) .
To clarify which DNA motif in the IFNB1 promoter conveyed the observed MafB effects, we cotransfected MafB expression plasmids with luciferase reporters containing multimerized forms of the DNA motifs PRDIII-PRDI (P31CS), PRDIV (AP-1) or PRDII (NF-κB), which bind the transcription factors IRF3 and IRF7, ATF2 and c-Jun, or NF-κB (subunits p50 and p65), respectively 11 . In unstimulated cells, the AP-1 motif was activated by MafB coexpression (Fig. 1g) , which suggested that this motif is responsible for MafB-mediated stimulation of basal activity of the IFNB1 promoter. After poly(I:C) treatment, the P31CS motif was strongly activated (> 50-fold), and this activation was potently inhibited by MafB coexpression (Fig. 1g) . Coexpression of MafB with a reporter based on the ISG54 interferon-stimulated response element (regulated by IRF3 and IRF7) confirmed these findings ( Supplementary Fig. 1c ). Mutation of the PRDIII-PRDI motif of the IFNB1 promoter to a form with diminished binding of IRF3 and IRF7 (ref. 12) led to less MafB-mediated inhibition of poly(I:C) induction ( Fig. 1h) . MafB had little inhibitory effect on the activation of NF-κB motif-dependent transcription by IFNB1 inducers or by MyD88, as exemplified by a mutant IFNB1 reporter containing the PRDII motif but lacking PRDIII-PRDI and PRDIV ( Fig. 1h) or by a multimerized NF-κB reporter (Supplementary Fig. 1d ). In addition, MafB did not inhibit activation of the intact IFNB1 promoter by tumor necrosis factor and phorbol myristate acetate (which act via NF-κB and AP-1 motifs, respectively), or of the PRDIII-PRDI mutant IFNB1 promoter by MyD88 (Fig. 1h) . These results are inconsistent with a mechanism of action of MafB predicated on nonspecific transcriptional suppression. The promoter of the gene encoding the chemokine RANTES (CCL5) was similarly regulated by MafB in a signal-dependent manner ( Supplementary Fig. 1c ), which indicated that the regulatory activity of MafB is not restricted to the IFNB1 promoter. The apparent action of MafB at AP-1 motifs is consistent with the observation that the canonical Maf-response element MARE contains an AP-1 motif as its core 3, 4 (Supplementary Fig. 1c ). Collectively, these data support the view that the stimulatory and inhibitory activities of MafB at the IFNB1 promoter segregate with the AP-1 site and the IRF3-and-IRF7-binding site, respectively, and that the inhibitory action of MafB at IRF3-and IRF7-binding sites is not confined to the IFNB1 promoter. A r t i c l e s (MEFs) can be contrasted with those of MEFs generated from their heterozygous Mafb +/− littermates 13 . In the basal state, the abundance of IFN-α and IFN-β mRNA was significantly higher in homozygous Mafb −/− MEFs than in heterozygous control Mafb +/− MEFs ( Fig. 2a) . Transcripts of genes induced by type I interferon signaling, such as Irf7 and Ddx58, also had higher expression in homozygous Mafb −/− MEFs than in heterozygous control Mafb +/− MEFs (Supplementary Fig. 2a ). Poly(I:C) treatment elicited significantly more IFN-α and IFN-β mRNA ( Fig. 2a ) and secreted IFN-β ( Fig. 2b) in homozygous Mafb −/− MEFs. The introduction of a plasmid encoding luciferase under control of the mouse Ifnb1 promoter showed that activation by poly(I:C) treatment or NDV infection was greater in homozygous Mafb −/− MEFs than in heterozygous Mafb +/− MEFs (Fig. 2c ). In addition, reintroduction of mouse MafB in Mafb-null MEFs attenuated Ifnb1 activation by poly(I:C) or NDV ( Fig. 2d) . In agreement with the more robust antiviral responses observed in the knockout Mafb −/− MEFs, VSV-Luc expression was lower in homozygous Mafb −/− MEFs than in heterozygous Mafb +/− MEFs ( Fig. 2e) .
MafB deficiency facilitates type I interferon production
Homozygous Mafb −/− MEFs grew more slowly than heterozygous Mafb +/− MEFs, which suggested that the chronic activation of type I interferon genes might retard growth. We assessed potential MafB influences on apoptosis induced by viruses or virus-mimetic signals by measuring caspase-3 activity in homozygous Mafb −/− and heterozygous Mafb +/− cells (Supplementary Fig. 2b ). We observed no difference between null and heterozygous MEFs in their caspase-3 activity in the absence of a viral trigger. However, after poly(I:C) treatment, caspase-3 activity was significantly greater in homozygous MEFs but not in heterozygous MEFs (P < 0.001; Supplementary Fig. 2b) .
We also found the general features of MafB-mediated regulation of the transcription of interferon genes to be present in human cells of diverse origin. Short hairpin or small interfering RNA targeting MafB mRNA ( Supplementary Fig. 2c ) promoted activation of the human IFNB1 promoter triggered by poly(I:C) treatment in 293ETN cells ( Supplementary  Fig. 2d ), HeLa human cervical adenocarcinoma cells and HT-1080 human fibrosarcoma cells ( Supplementary Fig. 2e ). These findings support the view that MafB is a broadly expressed transcription factor that has an important function in the restraint of IFNB1 promoter activity.
MafB interferes with IRF3 activity
The downstream signaling machinery common to RIG-I, Mda5 and TLR3 includes the kinases TBK1 and IKKε 14, 15 and the transcription factors IRF3 and IRF7 (refs. 16, 17) . Coexpression of MafB strongly repressed the induction of type I interferon mediated by the upstream effectors of IRF3 and IRF7, as well as IRF3 and IRF7 themselves, in 293ETN cells ( Fig. 3a) . We obtained similar results when we stimulated cells with poly(I:C) ( Supplementary Fig. 3a) . MafB repressed the IFNB1 activation mediated by a constitutively active form of IRF3, IRF3(5D) 18, 19 (Supplementary Fig. 3a) , which supported the interpretation that MafB functions at a step downstream of the carboxy-terminal (C-terminal) phosphorylation of IRF3 by TBK1 or IKKε. After transfection, we found MafB exclusively in the nucleus by immunohistochemistry ( Supplementary Fig. 3b ) and immunoblot analysis ( Supplementary  Fig. 3c ), and this localization was unaffected by viral infection, which suggested that the action of MafB is probably intranuclear.
In untransfected HeLa cells, the association of endogenous MafB with IRF3 was increased considerably after poly(I:C) stimulation without an increase in the abundance of MafB and IRF3 (Fig. 3b) . We obtained similar results with extracts of HepG2 human hepatocellular liver carcinoma cells ( Supplementary Fig. 4a ), which suggested that the association is not cell type specific. To evaluate the possibility that MafB interacts with IRF7, we transfected 293ETN cells with hemagglutinin-tagged MafB (HA-MafB) together with Flag-tagged IRF7 (Flag-IRF7). As a specificity control, we also examined the interaction of HA-MafB and Flag-TBK1. MafB associated with IRF7 but not with TBK1 in unstimulated cells ( Fig. 3c ). After poly(I:C) stimulation ( Supplementary Fig. 4b ), the interaction between MafB and IRF7 seemed to grow stronger, whereas MafB remained unassociated with TBK1.
Because MafB effectively suppressed activation of the IFNB1 promoter by a range of stimuli in HEC1B cells ( Supplementary Fig. 1a ), in which the inhibitory effect of MafB is probably mediated via IRF3 (ref. 20) , we explored potential interactions between IRF3 and MafB with a series of Flag-tagged IRF3 deletion mutants ( Fig. 3d ) and HA-MafB ( Supplementary Fig. 4c ). Full-length MafB immunoprecipitated together with full-length IRF3 and deletion mutants containing the C-terminal IRF-association domain but not with those containing the N-terminal portion of IRF3 ( Fig. 3d) . This finding demonstrated that the interaction between MafB and IRF3 requires an intact IRF-association domain of IRF3, whereas the N-terminal DNAbinding domain of IRF3 is dispensable for the MafB-IRF3 interaction. We detected all MafB deletion mutants after coimmunoprecipitation with IRF3 ( Supplementary Fig. 4c ). However, there were substantial disparities in MafB protein expression, and expression-normalized assessment suggested that the C-terminal basic leucine zipper domain of MafB contributes substantially to the association with IRF3, possibly by facilitating dimerization. MafB also exerted inhibitory influences on IRF7-dependent (but IRF3independent) transcriptional activation (Supplementary Fig. 5a ). Efficient binding of MafB to IRF7 required the N-terminal portion of IRF7, including the DNA-binding domain (Supplementary Fig. 5b ). Mafb IRF3 is located mainly in the cytoplasm in uninfected cells. After viral infection, IRF3 is activated through phosphorylation at C-terminal serine and threonine residues, which relieves an intramolecular autoinhibitory association. This conformational change leads to the formation of homodimers, accumulation in the nucleus, stimulation of DNA binding, association with the coactivator CBP or p300 and activation of type I interferon genes [19] [20] [21] [22] . Poly(I:C) stimulation substantially increased the formation of heterodimers between Flag-IRF3 and HA-IRF3, but MafB coexpression only weakly suppressed IRF3 dimer formation (Supplementary Fig. 6a ). We obtained similar results when we analyzed IRF3 dimerization by native PAGE in the presence of deoxycholate 20 (Supplementary Fig. 6b) .
To study the effect of MafB on the DNA binding of IRF3, we used electrophoretic mobility-shift assay with a PRDIII-PRDI (P31) oligonucleotide from the IFNB1 promoter or an interferonstimulated response element from the promoter of the gene encoding the ubiquitin-like modifier ISG15 as a probe (Fig. 4a ). The addition of in vitro-translated histidine-tagged MafB did not have an observable effect on the binding of immunopurified Flag-IRF3 to the P31 or ISG15 motif ( Fig. 4a) . Similarly, the addition of immunopurified Flag-MafB expressed in 293ETN cells did not have any effect on IRF3 binding (Supplementary Fig. 6c ). We obtained equivalent results with nuclear extracts prepared from HEC1B cells ( Supplementary  Fig. 6d ), which we transfected with IRF3(5D) tagged with Flag at the C terminus in the presence or absence of untagged MafB. We did not detect binding of MafB to the P31 motif, although we did detect weak binding of MafB to the PRDIV motif ( Supplementary Fig. 6e) .
We explored the effect of MafB on the recruitment of IRF3 to the IFNB1 promoter in vivo by chromatin immunoprecipitation followed by quantitative PCR. We detected enrichment of IFNB1 promoter sequences in immunoprecipitates of endogenous IRF3 from HeLa cells ( Fig. 4b) and transfected 293ETN cells (Fig. 4c) , and the enrichment was significantly enhanced by poly(I:C) stimulation. Coexpression of MafB had either limited or no inhibitory effect on IFNB1 promoter enrichment by activated IRF3 (Fig. 4c) . We confirmed those results by experiments relying on coexpression of IRF3(5D) and its Flag-tagged form (Fig. 4c) .
In addition, we examined whether MafB could be directly recruited to the IFNB1 promoter. Immunoprecipitation of endogenous MafB produced robust enrichment of IFNB1 promoter sequences from chromatin prepared from unstimulated HeLa cells, but after poly(I:C) stimulation, the enrichment diminished (Fig. 4b) . We obtained similar results for transfected 293ETN cells expressing Flag-MafB ( Fig. 4d) : promoter binding was compromised by IRF3 coexpression and particularly by coexpression of constitutively activated forms of IRF3. Together these results indicate that MafB does not substantially interfere with binding of IRF3 by DNA. Instead, IRF3 seems to displace MafB after activation, and hence the action of MafB must lie subsequent to IRF3 binding.
To clarify the mechanism of MafB transcriptional suppression, we turned to the analysis of fusion proteins of the yeast transcriptional activator Gal4 and IRF3 (Gal4-IRF3). MafB suppressed the activity of Gal4-IRF3 (Fig. 4e) . The transcriptional activity of a fusion of Gal4 with IRF3 amino acids 1-394, lacking the C-terminal activation domain, was not increased by poly(I:C) stimulation, and MafB had little effect on transactivation by the truncated fusion, although the basal activity was somewhat higher than that of Gal4-IRF3, possibly attributable to a conformational change to an open structure [19] [20] [21] [22] (Fig. 4e) . These data suggested that MafB interferes with functions of IRF3 mediated via the five C-terminal serine-threonine residues.
Further support for the idea that MafB acts downstream of IRF3 binding was provided by the finding that a DNA binding-defective mutant of MafB 23 retained its inhibitory ability at the IFNB1 promoter ( Supplementary Fig. 7a ), although its transcriptional activity at MARE motifs was considerably impaired (Supplementary Fig. 7b ), which suggested that binding of MafB to the IFNB1 promoter is not a required element of the inhibition process 24 . Because the IRF3 C terminus can facilitate the recruitment and activation of the coactivators p300 and CBP [19] [20] [21] [22] , we explored the possibility that MafB directly interferes with IRF3-CBP interactions. We observed a strong association between Flag-IRF3(5D) and CBP ( Fig. 4f) and between Flag-IRF3 and CBP after poly(I:C) stimulation (Fig. 4f) . The introduction of MafB or its Flag-tagged form considerably impaired the association of CBP with activated forms of IRF3 (Fig. 4f) . The relative strengths of IRF3-CBP interactions ( Fig. 4f and Supplementary Fig. 7c ) showed good correlation with the transactivation induced by Gal4-IRF3 fusion proteins (Fig. 4e) . Collectively, these results support the view that interference with IRF3-CBP interactions by MafB was mainly responsible for the observed MafB-mediated inhibition of IRF3 and its Gal4 fusion proteins (Figs. 3a and 4e and Supplementary Fig. 3a) .
Ectopic expression of CBP did not lead to any observable reversal of the MafB-mediated inhibition of IRF3-triggered IFNB1 activation (Supplementary Fig. 7d ). MafB did not act in synergy with CBP at the IFNB1 promoter ( Supplementary Fig. 7e ), and we were not able to document any interaction between overexpressed CBP and MafB. MafB also did not inhibit transactivation by the transcription factor PPAR-γ or the PPAR-γ coactivator PGC-1α ( Supplementary Fig. 7f ), which can act in synergy with CBP to activate transcription 25 . These results indicate that MafB does not compete with IRF3 for binding to CBP but instead competes with CBP for binding to IRF3. We also examined whether sumoylation of MafB was involved in the inhibition of type I interferon induction. All of the single and double sumoylation-deficient mutants of MafB 26 were as effective as wild-type MafB in repressing poly(I:C)-mediated activation of IFNB1 (Supplementary Fig. 7g ), which indicated that the sumoylation status of MafB is not linked with its ability to repress IFNB1 activation. Together, the foregoing results indicate that MafB acts as a transcriptional antagonist of type I interferon induction mainly by impairing recruitment of the transcriptional coactivator CBP to IRF3.
Cellular regulation of MafB expression
We next investigated how the expression of MafB varies in response to a viral trigger. MafB expression in 293ETN cells decreased after poly(I:C) stimulation (Fig. 5a) , and the expression of MafB over time was inversely correlated with that of IFN-α and IFN-β ( Fig. 1d,e) . Expression of c-Maf, another member of the large Maf family protein, also decreased in 293ETN cells in response to poly(I:C) stimulation (Fig. 5a) , and c-Maf suppressed IFNB1 activation triggered by a range of type I interferon inducers, including poly(I:C), RIG-I(N) and Mda5(N) (Supplementary Fig. 8a) . Expression of the large Maf transcription factors MafA and NRL was modest compared with that of MafB and c-Maf in 293ETN cells (data not shown). The change in MafB abundance differed from that of other reported negative regulators of type I interferon signaling pathway 2 such as Tnfaip3 (A20), Otud5 (DUBA) and RNF125, whose expression is upregulated by viral triggers. The attenuation of MafB expression after induction suggested that MafB acts principally to restrain type I interferon production in response to normal cellular fluctuations.
We also analyzed the regulatory patterns of MafB expression in a variety of cell types in response to pathogen-mimetic stimulation using publicly available microarray data sets, including the Gene Expression Omnibus database [27] [28] [29] [30] [31] [32] (Fig. 5b-e and Supplementary Fig. 8b-e) . In most cases, we observed that MafB expression decreased in response to a pathogen-mimetic stimulus, whereas expression of IFN-α and IFN-β and genes regulated by IFN-α and IFN-β signaling increased. We did not detect any systematic correlations for c-Maf or NRL, and in many cases their expression was negligible compared with that of MafB. These results, combined with the broader tissue distribution of MafB expression than that of other large Maf family members (found on the BioGPS Gene Portal Hub website), suggest a general, lineagenonspecific role for MafB. However, we encountered some exceptions. For example, in HeLa cells, MafB expression increased slightly after poly(I:C) stimulation, and induction of type I interferon was much weaker in HeLa cells than in 293ETN cells (Supplementary Fig. 8f ). Expression of MafB (Fig. 5f ) and c-Maf (Supplementary Fig. 8g ) was higher in a hepatitis C virus replicon-containing cell line selected to be highly permissive for the replication of hepatitis C virus RNA 33 . The higher MafB expression may have been virus dependent, as inhibition of hepatitis C virus replication by treatment of these cells with the cyclophilin inhibitor cyclosporin A resulted in much lower MafB expression in the infected line but had little effect on the uninfected parental line. These results raise the possibility that viruses induce MafB as a strategy for suppressing type I interferon responses.
Mathematical modeling of type I interferon induction
MafB had both stimulatory and inhibitory effects on the IFNB1 promoter depending on the experimental conditions (Fig. 1a) .
To provide a quantitative framework for understanding MafB-mediated regulation of the induction of type I interferon, we developed a With this model, we identified several key factors that influence the potency of MafB as an inhibitor of IFNB1 induction: high-order interactions of MafB and IRF3 on the IFNB1 promoter and in the nucleoplasm, and a low-order interaction of MafB and the IFNB1 promoter, which affected the IFNB1 promoter activity in opposing directions (Supplementary Fig. 9b-g) . The model suggested that MafB, even in relatively small amounts, exerts a considerable inhibitory effect on IFNB1 induction, mainly by a high-order interaction of MafB with IRF3 on the promoter that resulted in inhibition of the formation of a IRF3-CBP preinitiation complex (Supplementary Fig. 9e,f) . These findings are in agreement with the experimental observations obtained with genetically deficient MEFs. Rapid and strong induction of IFNB1 in 293ETN cells in response to a viral elicitor can be ascribed to a substantially enhanced processing rate and higher efficiency of a preinitiation complex for generating a productive polymerase II elongation complex (Supplementary Fig. 9h) . The model suggests that a complex between MafB and IRF3 in the nucleoplasm provides a mechanism to effectively buffer unwarranted low activation of IFNB1 and, at the same time, in combination with MafB downregulation ( Supplementary  Fig. 9i ), to counteract this buffering role of MafB to facilitate the IFNB1 activation after viral infection (Supplementary Fig. 9j-n) .
MafB and enterovirus infection of pancreatic beta cells
The finding that MafB expression might predispose cells to viral infection suggested that cells with high expression of MafB could be vulnerable to viruses. For example, enteroviruses such as coxsackievirus are able to infect pancreatic tissues, and such infection might be a trigger for the development of type 1 diabetes 34, 35 . Enterovirus infection is specific to endocrine pancreatic islet cells but not to the exocrine pancreas in humans 35, 36 . The known enterovirus tropism showed good correlation with the pancreatic expression pattern of MafB in humans 37 (Fig. 6a) . Furthermore, MafB expression was higher in purified human beta cells 38 (Fig. 6b) , which constitute over 60% of the islet population 32 , than in the islets themselves, which suggested that in humans, relatively high MafB expression is maintained in mature beta cells. In contrast, in mice, enterovirus infection of healthy islets is limited even in lethal cases 35, 39 , consistent with the relatively low MafB expression in adult mouse islets 7 . MafB expression is restricted to alpha cells in the adult mouse, although expression is found both in alpha and beta cells in the mouse embryo.
To determine whether the differences in MafB expression might have a role in the observed cell tropism and species selectivity of enterovirus infection, we ectopically expressed human MafB in the mouse pancreatic beta-cell line MIN6 and monitored cellular antiviral responses. Coexpression of MafB resulted in strong inhibition of activation of the mouse Ifnb1 promoter triggered by RIG-I(N) and Mda5(N) (Fig. 6c) .
In addition, MafB expression enhanced replication of VSV-Luc more than mock transfection did (Fig. 6d) . Because type I interferon might have an essential role in preventing beta-cell destruction induced by coxsackievirus infection 40 , it is possible that higher MafB expression in human islet cells might predispose these cells to coxsackievirus infection or persistence, thereby increasing susceptibility to type 1 diabetes. Mafb is a candidate gene located in the type 1 diabetes susceptibility locus Idd13 in nonobese diabetic NOD/ShiLtJ mice 41 . Coxsackievirus replicates in the islet tissue of older prediabetic NOD mice 42 . To explore whether MafB has a role in the age-dependent susceptibility of NOD mice to enterovirus infection, we monitored MafB expression in islet tissue. To avoid potential confounding effects of macrophage infiltration in islets, we selectively collected the beta cell-rich core of islets by laser-capture microdissection. We detected a greater abundance of MafB transcripts in older NOD mice with severe hyperglycemia (blood glucose over 500 mg/dl) than in younger NOD mice before the onset of hyperglycemia (Fig. 6e) . Expression of the macrophage-specific marker F4/80 (encoded by Emr1) was below the limit of detection for all samples collected by laser-capture microdissection (data not shown). We obtained similar results for whole islets isolated from NOD mice by a conventional collagenase perfusion technique 43 (Fig. 6f) ; in these, the two age groups showed similar amounts of macrophage infiltration. These results support the proposal that age-dependent accumulation of MafB contributes to the observed susceptibility of older prediabetic NOD mice to enterovirus infection 42 . The extent to which endemic enteroviruses contribute to the etiology of diabetes in the NOD strain is unknown at present, but the variable course and age dependence are consistent with the influence of a stochastic environmental event. Species-and strain-specific, lineage-dependent MafB expression can be predicted to contribute to susceptibility of islet beta cells to viral infection, a susceptibility that might contribute to human susceptibility to type I diabetes.
DISCUSSION
The results from studies of MEFs from MafB-deficient embryos in this work support the view that the low MafB expression found in nearly all mammalian tissues has functionally important consequences for antiviral responses. There is ample support for the view that even in the absence of viral infection, cells are constitutively exposed to low activation signals that could initiate the production of type I interferon, as shown by the low constitutive phosphorylation observed for IRF3 and IRF7 (refs. 20,21) . Spontaneous induction of type I interferon should be tightly regulated in uninfected cells, as chronic activation diminishes host fitness, facilitates autoimmune disease and induces tissue injury. We propose that as a constitutive inhibitor of the type I interferon pathway, MafB buffers cells against unwarranted induction of type I interferon. In uninfected cells, MafB proteins might be located near the type I interferon promoters or other IRF3-regulated genes, an affiliation presumably mediated by nearby AP-1 or MARE motifs, and have weak transcriptional activity. After adventitious binding of activated IRF3 to the promoter, MafB masks IRF3 from CBP by binding to the C-terminal IRF-association domain of IRF3, inhibiting interaction of IRF3 and CBP and thereby preventing the formation of functional preinitiation complexes. MafB might also bind to IRF3 in the nucleoplasm, interfering with cofactor-mediated recruitment of IRF3 to the relevant promoters. After viral infection, the flow of activated IRF3 from cytoplasm to nucleus and the recruitment of IRF3 to relevant promoters increase substantially. Furthermore, the binding of IRF3 to MafB in the nucleoplasm might counteract the MafB-mediated inhibition by diminishing the pool size of free MafB as recruitment of IRF3 to the promoters increases, accelerating the production of type I interferon, which is further amplified by its positive feedback loop. MafB expression might be downregulated, depending on the cell type, to facilitate IRF3-dependent transactivation. In this way, MafB could create an inhibitory threshold for the induction of active type I interferon, with the exact nature of this threshold determined by cell type-specific MafB expression and its regulation. The dual role of MafB as activator and coactivation inhibitor might be intrinsically linked by the colocation of MafB and its target transcription factors in the chromatin neighborhood of highly sensitive promoters, thereby preventing stochastic fluctuation from eliciting runaway amplification.
The mechanism of inhibitory action of MafB described here is distinct from that of previously described repressors, as unlike IRF2 (ref. 44 ), MafB bound directly to IRF3 and IRF7 and did not directly inhibit NF-κB-dependent transactivation. In addition, unlike Pin1 (ref. 45) , which targets IRF3 for ubiquitination and subsequent proteasome-mediated degradation, MafB coexpression did not decrease IRF3 protein abundance. The dual mode of action of MafB as activator and coactivation inhibitor is distinguishable from that of the glucocorticoid receptor, a well-documented dual regulator of transcription 46 , as the MafB activity did not depend strongly on its direct association with CBP.
In addition to its effects on IRF3, MafB might also exert inhibitory influences on IRF7-dependent transcriptional activation under physiological conditions. For example, in cell types with high constitutive IRF7 expression, such as plasmacytoid dendritic cells and macrophages, cells should also restrain ectopic induction of IRF7-dependent transcription. Our results, combined with evidence of higher expression of MafB in these cells than in other cell types (available on the BioGPS Gene Portal Hub website), suggest that MafB might also be important in this process. However, the mode of action of MafB on IRF7 might differ from that observed for IRF3, as viral infection induces substantial recruitment of CBP to IRF3 but not to IRF7 (refs. [18] [19] [20] [21] , and efficient binding of MafB to IRF7 requires the DNA-binding domain of IRF7, which raises the possibility that MafB interferes with the binding of IRF7 to DNA. Furthermore, our mathematical model suggests that in cell types with higher expression of MafB, regulation of the recruitment and binding of an interferon-inducing transcription factor to a relevant promoter might constitute a primary mode of action of MafB for controlling IFNB1 activation, which supports the view that MafB functions as a constitutive inhibitor of IRF7-dependent transactivation in these cells. We also found that unlike TBK1, MafB showed substantial binding to IKKε, which, combined with its inhibitory effect on IRF7, raises the possibility that MafB also functions to inhibit late-phase interferon signaling.
Regulation of MafB expression in response to pathogen triggers, combined with the unstable nature of MafB protein 47 , its weak transforming activity 47 and its ability to strongly repress the induction of type I interferon, might enable host cells to respond rapidly to viral pathogens. MafB has a myeloid expression pattern with prominent transcription in monocytes and macrophages 5, 6 , which indicates that it broadly shapes the innate immune potential of the organism toward an antibacterial ability (that is, monocytic or macrophage) instead of an antiviral ability (dendritic cell). Because MafA has high expression in mature beta cells and might have a fundamental role in regulating survival and function of these cells 7, 8 , MafB might be dispensable or at least not central for islet function, and hence therapeutic inhibition of MafB with the intention of clearing islet infection might not have adverse consequences for glucose homeostasis. Collectively, our results raise the possibility that MafB expression and regulation have important consequences for type I interferon responses and indicate that a lineage dependence of viral susceptibility could have important consequences for diseases of viral or autoimmune etiology.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
